Viswanatha Allugunti

Linus Liang

Linus is the Founder and Managing Partner of Kyber Knight Capital. He brings over twenty-five years of experience in venture capital and entrepreneurship to his leadership role. Before starting Kyber Knight Capital, Linus spent a decade at Signia Ventures, where he continues as a Partner. His entrepreneurial pursuits include co-founding Embrace, the company behind the world’s most affordable infant incubator. To date, Embrace has impacted the lives of over 500,000 infants worldwide in over a dozen countries.

Before Embrace, Linus founded several software companies focusing on mobile technology and social networking. He is well known for joining Zynga’s founding team, following the acquisition of his start-up, where he served as the tenth employee.

Linus’s career also encompasses roles at major corporations, including Program Manager at Microsoft, database researcher at IBM, and a member of the investment team at Andreessen Horowitz.

Linus is a holder of a B.A. in Computer Science from U.C. Berkeley, as well as an M.S. in Computer Science, an M.A. in Education, and an MBA from Stanford University. He is a co-instructor for Stanford’s Frontier Technologies course and has previously taught a Big Data class at Stanford’s Business School.

Kevin Tsai

Kevin currently leads a team of Solution Architects with focus on Generative AI and large-scale, accelerated infrastructure. Kevin has also led teams in Data Analytics, Data Management, and ML at Google, and has more than 20 years of experience in the technology industry

Peter Clark

Peter Clark, PhD is the Head of Computational Science & Engineering within the Therapeutics Discovery (TD) organization of Janssen R&D, where he leads a dynamic, interdisciplinary team of scientists focused on accelerating the research and development of protein based therapeutics through the design and implementation of disruptive computational approaches and platforms. Prior to joining Johnson & Johnson, Peter served as the Director of Bioinformatics at the University of Pennsylvania, Perelman School of Medicine, where he worked closely with academic and commercial collaborators on the design, optimization, and evaluation of various gene therapy platform technologies from early research and development through commercially partnered IND enabling clinical studies. Peter is also a clinically trained molecular pathologist (The Children’s Hospital of Philadelphia) with extensive experience in the design, validation, and implementation of diagnostic and prognostic next generation sequencing (NGS) assays within a clinical, CAP/CLIA certified laboratory setting. During his clinical molecular pathology fellowship at CHOP, Peter co-developed and commercialized the first to market, high resolution, next generation sequencing based HLA genotyping assay and was subsequently awarded the Scholar of the Year award by the American Society for Histocompatibility and Immunogenetics (ASHI) in 2015 for his contributions to the field of solid organ and bone marrow transplantation. Peter earned his B.Sc. and Ph.D. from Drexel University, School of Biomedical Engineering prior to completing a postdoctoral fellowship at The Center for Computational Medicine at Thomas Jefferson University.  Peter’s diverse expertise in computational science, engineering, clinical molecular genetics, computational biology, and translational research has led to the publication of over 30 peer-reviewed scientific publications as well as two book chapters, several issued patents and three biotechnology spin-off companies.